Trinity Partners Releases New Report on Oncology Basket Trials

Leading global life sciences consulting firm Trinity Partners today released a new whitepaper analyzing the oncology clinical trial pipeline to determine the extent to which basket trials are being utilized and, in particular, how many are likely to be registrational studies resulting in tissue-agnostic indications.

Historically, basket trials have been used to explore multiple tumor types in one trial in order to prioritize the ones with the greatest response for further research. However, with Keytruda’s MSI-H and dMMR approval, basket trials have now become a viable registrational strategy to pursue a tissue-agnostic indication. Key findings from the whitepaper include:

  • Only 2 trials appear to clearly be pursuing a tissue-agnostic regulatory filing; there are no basket trials currently in Phase III.
  • Although many of the trials identified are not clearly linked to a planned regulatory filing for a tissue-agnostic indication, the authors expect that the results of these trials, if positive in the broad indication, could lead to future registrational trials in the next 1-3 years.
  • Across the 37 basket trials identified for analysis, 16+ types of biomarkers or genetic mutations are currently being studied. This broad scope verifies the growing trend of tumor-agnostic research across oncologic agents, regardless of biomarker studied.

“In the near term, pending the results of these trials, interest in tissue-agnostic basket trial development is likely to grow, especially as next-generation genomic sequencing continues to become more widespread in oncology,” said Jillian Godfrey Scaife, principal at Trinity Partners. “Whether the number of tissue-agnostic indication approvals will ever be substantial enough to drive a significant shift in treatment approaches remains an open question.”

“With this research, we sought to better understand whether and when there will be a tipping point in the oncology treatment paradigm,” added Vivian DeWoskin, engagement manager. “The growing pool of mid-phase/exploratory tissue-agnostic trials suggests we could be headed in that direction, leading to many long-term implications on the clinical application, commercialization and development of targeted oncolytics in the next several years.”

Trinity works with more than 100 clients annually, including 18 of the top 25 global biopharmaceutical companies and dozens of leading medical device and diagnostic companies. Trinity has over 150 professionals on staff that focus solely on the life sciences industry.

To view the full whitepaper, click here.

Trinity Employees Share Expertise at Leading Spring Events and Conferences

Boston, MA, May 15, 2018 – Trinity Partners, a leading global life sciences consulting firm, today announced it will attend several important industry events across the U.S. this month. Covering topics ranging from innovation and endocrinology research to managed care, Trinity leaders are looking forward to presenting on and learning the latest updates in rare disease and patient advocacy, health care expenditure and the patient journey to continue to help clients make informed decisions in today’s continuously evolving business landscape.

Life sciences industry events Trinity Partners will attend include:

  • Intellus Worldwide Summit, May 6-8: Steve Yonish, Kyle Martin and Devon Reimer attended the Intellus Worldwide Summit in Philadelphia. The summit focused on new ways of understanding the patient journey including how insight professionals think about and provide solutions to optimize the patient experience.
  • Innovation Leader’s Deep Dive: Transforming Healthcare, May 16-17: Matt Giambrone will participate in the Innovation Leader’s Deep Dive at the Pulse@MassChallenge healthcare accelerator in Boston to hear best practices to better enable healthcare companies to successfully foster, pilot test and roll out new concepts.
  • American Association of Clinical Endocrinologists (AACE) 27th Annual Scientific and Clinical Congress, May 16-20: Irana Kolev will attend the AACE Scientific and Clinical Congress to hear the latest information on the diagnosis and management of endocrine diseases. Irana will also be presenting a poster for a recent Trinity health economics outreach research (HEOR) study on chronic hypoparathyroidism on May 19 from 10-11 am ET.
  • International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 23rd Annual Meeting, May 19-23: Nandini Hadker, Gavin Miyasato, Zahra Alkhateeb, Amod Athavale and Kalin Hennegan will be attending the ISPOR Annual Meeting in Baltimore to engage in the latest discussions around the role of real-world evidence and digital health in healthcare decision making. Trinity will also be presenting research in 3 poster presentations during ISPOR: a Medicare claims analysis quantifying the degree and impact of multiple sclerosis, amyotrophic lateral sclerosis and Alzheimer’s disease sub-specialization among neurologists, along with a Burden of Illness study and systematic literature review assessing the challenges with characterizing and managing hypoactive sexual desire disorder in women.

“At Trinity, we are committed to continuous learning and innovation to ensure we’re at the forefront of topics that matter to our clients,” said Yogesh Soneji, Partner, Trinity Partners. “We look forward to presenting research and continuing to find solutions to the complex business challenges that confront pharmaceutical, biotech, and medical device companies around the globe.”

Trinity Partners to Present on Patient Journey at Eyeforpharma Philadelphia 2018

Boston, MA, April 10, 2018 – Trinity Partners, a leading global life sciences consulting firm, today announced it will participate in eyeforpharma’s 16th Annual Meeting, April 10-11, in Philadelphia, PA.

This year’s eyeforpharma meeting is designed to provide life sciences executives with greater insight into the patient journey. Presenters will highlight strategies to leverage advanced analytics and communication channels and unite organizations around the patient to deliver real value.

“Treatments are becoming more targeted and patients are more involved in the treatment-decision-making process. Whether a product is launched or in clinical development, it’s vital that drug manufacturers understand a patient’s treatment journey from all perspectives – from the patient to the provider to the payer – to make more informed commercial decisions,” Kevin Francis, Principal, Analytics & Insights, Trinity Partners. “We look forward to attending eyeforpharma, connecting with members of the life sciences community and showcasing how to mine the patient journey for insights to guide commercial strategy decision-making.”

At eyeforpharma, Kevin Francis and Jenn Parr, Engagement Manager, will present on understanding and continuously refining the patient treatment journey to help manufacturers along the commercial decision-making process. The session, titled “Commercial Strategy Decision-Making powered by the Patient Journey” will be held on April 10, 2018 from 5:25-5:55 pm.

During the session, Kevin and Jenn will highlight how organizations can develop a patient journey framework that enables a common language across commercial teams, informs data strategy, and provides insights across the product development cycle. Kevin and Jenn will also showcase specific examples for organizations that have leveraged the patient journey for clinical, launch and post-launch decision-making purposes.

Visit Trinity at booth #4 at eyeforpharma to learn more about how you can begin to use the patient journey as the backbone for commercial decision-making.

Trinity employees will also attend several other events and conferences this month focused on gene therapy, rare diseases, specialty pharmacy and more. Events include:

  • The 2018 Yale Healthcare Conference: April 13, New Haven, CT
    • Nandini Hadker will speak on a panel on drug pricing.
  • The Academy of Managed Care Pharmacy (AMCP) 2018 Annual Meeting: April 23, Boston, MA
  • World Orphan Drug Congress USA: April 25, Oxon Hill, MD
  • Asembia’s 2018 Specialty Pharmacy Summit: April 29, Las Vegas, VM
  • The Gene Therapy for Rare Disorders Summit: April 29, Boston, MA

Trinity Partners Principal Jillian Godfrey Scaife Discusses Trinity Biosimilar Whitepaper

In a recent article for Managed Healthcare Executive, editor Tracey Walker spoke with Trinity’s Jillian Godfrey Scaife about the findings of Trinity’s recent biosimilar whitepaper. In the article, Jillian highlights key takeaways from the findings. You can read the full story including further insights from Jillian here: http://bit.ly/2Br1FsD

Trinity’s John Greenway and Nick Simmons-Stern to Present Case Study at CBI’s Biosimilar Summit

John Greenaway, Jillian Scaife, Nick Simmons-Stern, Ali Haber, and Christina Danosi are traveling to Alexandria, Virginia this week to attend CBI’s Biosimilars Summit. At the conference, they’ll discuss how to overcome reimbursement hurdles in an expanding U.S. biosimilars market. Learn more about the event here: http://www.cbinet.com/conference/pc18014

Trinity Partners Director of Advanced Analytics, Todd Foster to Attend PMSA’s Winter Symposium

Todd Foster, Trinity’s director of advanced analytics, will attend the PMSA’s Multi-Channel Marketing Symposium in Las Vegas, January 18 – 19 2018. During the event, Todd will meet with fellow industry leaders to discuss innovative marketing practices that use data to elevate multi-channel marketing for the biotechnology, medical and pharmaceutical industries. Learn more about the event here: http://bit.ly/2FIL3MS

Senior Partner Leslie Sandberg Orne Discusses Top Drugs for 2018

In a recent article for Formulary Watch, editor Christine Blank spoke with Trinity’s Leslie Sandberg Orne about new blockbuster drugs to hit the marketplace in 2018 that will treat HIV, diabetes, cancer, migraine headaches and other conditions. Check out Leslie’s insights in the full article, here: http://bit.ly/2ArPeZz

Trinity’s Herman Sanchez, Alex Chiang and Vivian DeWoskin attended the American Society of Hematology (ASH) Annual Meeting in Atlanta

On December 9th, Trinity’s Herman Sanchez, Alex Chiang and Vivian DeWoskin attended the American Society of Hematology (ASH) Annual Meeting in Atlanta, GA. During the meeting, Trinity employees had the opportunity to receive insight on evidence-based practice and decision making around malignant and non-malignant hematology, as well as the controversies associated with diagnosis and management. A full agenda of the annual meeting
can be found here: http://bit.ly/2zCT0Q5

Our Managing Partner Dave Fitzhenry recently sat down with Brian Orelli from BioWorld Insight

Our Managing Partner Dave Fitzhenry recently sat down with Brian Orelli from BioWorld Insight where he discussed the findings of our second annual Drug Index. In the article titled, “Winners and losers from the FDA approval class of 2014,” Dave provided a comprehensive overview of the commercial success and performance of each individual drug humorously highlighting how Trinity Partners “envisioned it like looking at NFL draft grades.”

Experts from Trinity Partners and Janssen Publish Article in Dermatology and Therapy

A team of experts from Trinity Partners and Janssen have published an article in Dermatology and Therapy. The paper, titled, “Dermatologist and Patient Preferences in Choosing Treatments for Moderate to Severe Psoriasis,” describes the results of a study to determine dermatologist and patient preferences in choosing treatments for moderate to severe psoriasis. The study concluded that comprehensive education regarding treatment attributes may help minimize the influence of subjective biases and facilitate appropriate and patient-centered treatment selection in psoriasis.

The paper was authored by Gordon Lau, Gretchen R. Chiu, Nandini Hadker, Aparna Deshpande, Stephen Fleming, and Nicola Vance, all of Trinity Partners, along with Seina Lee and Steve Fakharzadeh of Janssen Scientific Affairs. At the time of the study, Matthew Alcusky was a postdoctoral fellow with Thomas Jefferson University and Janssen Scientific Affairs.

To view the full text of the article, please visit http://bit.ly/2hJqe9k